After the success of the Mercurius study in 40 European dialysis centres, this study was also conducted in 2 Canadian hospitals (Toronto General Hospital and Grand River Hospital).
Customer: Amgen Canada
Main Goal: Determine the qualitative and quantitative impact of less frequent dosing of ESAs in chronic HD patients, and strengthen the partnership of Amgen Canada with 2 key accounts by performing process analyses and improvements for these participating hospitals
Main Result: Report on the impact of less frequent dosing for these 2 hospitals (incl. scientific poster), process optimization recommendations for both hospitals and strengthening the partnership between Amgen and the 2 Canadian hospitals
The objective of the study in Canada:
For this analysis an impact model (geared to the Canadian market) was developed, consisting of a conceptual model, a generic model and a hospital-specific model: